

Ophthalmic Topical Therapeutics Market Forecast till 2030

Market Report | 2023-11-15 | 148 pages | Market Research Future

AVAILABLE LICENSES:

- Single User Price \$4950.00
- Enterprisewide Price \$7250.00

Report description:

Ophthalmic Topical Therapeutics Market Forecast till 2030

Market Overview

The Ophthalmic Topical Therapeutics is estimated to register a significant CAGR of 7.25% during the forecast period (2023 - 2030).

This market is being driven by a few elements, remembering an ascent for geriatric populace and expanding pervasiveness of ophthalmic problems.

There is a rising commonness of ophthalmic problems like refractive blunders, dry eye, glaucoma, eye sensitivities, and age-related macular degeneration internationally which is driving the market development. As per the WHO in October 2021, somewhere around 2.2 billion individuals universally experience the ill effects of vision weakness. The main sources of vision hindrance are refractive blunders and waterfall, the two of which have topical ophthalmic restorative items accessible on the lookout. Essentially, glaucoma is a main source of irreversible visual impairment universally. As indicated by Public Glaucoma Exploration, north of 3 million Americans have glaucoma. As per the WHO in 2021, over 7.7 million individuals experience the ill effects of glaucoma worldwide. The most widely recognized treatment for glaucoma is remedy eye drops like beta-blockers, prostaglandins, Rho-kinase inhibitors, and others that can hold glaucoma back from deteriorating.

Market Segmentation

The Market fragments of Ophthalmic Topical Therapeutics, based on type, incorporates fake tears, against sensitivity, anti-toxin drops, mitigating, antiglaucoma, and others. The Market division, in view of disease type, incorporates dry eye, eye sensitivity, glaucoma, eye disease, retinal issues, uveitis, and others. In view of dose form, the worldwide ophthalmic topical therapeutics industry is divided into eye drops, gels, salves, and others.

The Market division of Ophthalmic Topical Therapeutics, in view of distribution channel, incorporates clinic drug stores, pharmacies, online drug stores, and others.

Regional Insights

The North America ophthalmic topical therapeutics market represented the biggest piece of the pie in 2022. Key variables credited to its rising commonness of eye sickness, rising geriatric populace, and the presence of an enormous number of market

Page 1/10

Scotts International, EU Vat number: PL 6772247784

players in the district. Moreover, the rising commonness of ophthalmic illnesses is driving the market interest for ophthalmic topical therapeutics in North America. Factors like an expansion in the geriatric populace, progressions in innovative work in optometry, and the expansion in the utilization of ophthalmic medications in emergency clinic drug stores are supposed to expand the interest for ophthalmic topical therapeutics in the US.

Europe ophthalmic topical therapeutics market represented the second-biggest piece of the pie because of expanding geriatric populace in the created nations, globalization of medical services, and rising weight of diabetes and other comorbidities.

The Asia-Pacific ophthalmic topical therapeutics market is supposed to be the quickest developing from 2023 to 2030 because of the rising expanding weight of ophthalmic problems and rising buyer mindfulness, and the developing reception of cutting-edge innovations. Organizations are going into key drives to create and popularize new treatment choices for patients.

Major Players

Key Companies in the market of ophthalmic topical therapeutics includes Santen pharmaceutical co., Ltd. (Japan), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), AbbVie (US), Bausch & Lomb Incorporated (US), Amneal Pharmaceuticals., LLC (US), Teva Pharmaceutical Industries Ltd. (Israel), Alcon (Switzerland), Akorn Operating Company LLC (US), and Viatris Inc. (US).

Table of Contents:

TABLE OF CONTENTS

- 1 EXECUTIVE SUMMARY
- 1.1 OVERVIEW
- **2 MARKET INTRODUCTION**
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 MARKET STRUCTURE
- 2.5 ASSUMPTIONS & LIMITATIONS
- 3 RESEARCH METHODOLOGY
- 3.1 DATA MINING
- 3.2 SECONDARY RESEARCH
- 3.3 PRIMARY RESEARCH
- 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
- 3.5 FORECASTING TECHNIQUES

Scotts International, EU Vat number: PL 6772247784

3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISE IN GERIATRIC POPULATION
4.2.2 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS
4.3 RESTRAINTS
4.3.1 LACK OF AWARENESS REGARDING EYE DISORDERS
4.4 OPPORTUNITIES
4.4.1 GROWING NUMBER OF TOPICAL DRUGS IN THE PIPELINE
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

Scotts International. EU Vat number: PL 6772247784

5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE OPHTHALMIC TOPICAL THERAPEUTICS MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTTION
5.3.3 IMPACT ON MARKET PLAYERS
6 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 ARTIFICIAL TEARS
6.3 ANTI-ALLERGY
6.4 ANTIBIOTIC DROPS
6.5 ANTI-INFLAMMATORY
6.6 ANTIGLAUCOMA
6.7 OTHERS
7 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE
7.1 OVERVIEW
7.2 DRY EYE
7.3 EYE ALLERGY
7.4 GLAUCOMA
7.5 EYE INFECTION
7.6 RETINAL DISORDERS
7.7 UVEITIS
7.8 OTHERS

8 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM
8.1 OVERVIEW
8.2 EYE DROPS
8.3 GELS
8.4 OINTMENTS
8.5 OTHERS
9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 HOSPITAL PHARMACIES
9.3 DRUG STORES
9.4 ONLINE PHARMACIES
9.5 OTHERS
10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE

10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
11.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
11.5 KEY DEVELOPMENT ANALYSIS
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT APPROVALS AND PRODUCT LAUNCHES/PIPELINE DRUGS
11.6.2 PARTNERSHIP/COLLABORATION
11.6.3 BUSINESS EXPANSIONS/AGREEMENTS
11.6.4 MERGERS & ACQUISITIONS
11.7 MAJOR PLAYERS SALES ANALYSIS

11.8 MAJOR PLAYERS R&D ANALYSIS
12 COMPANY PROFILES
12.1 SANTEN PHARMACEUTICAL CO., LTD.
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 KEY STRATEGIES
12.2 SUN PHARMACEUTICAL INDUSTRIES LTD
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 KEY STRATEGIES
12.3 NOVARTIS AG
12.3.1 COMPANY OVERVIEWS
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 ABBVIE INC.
12.4.1 COMPANY OVERVIEW

11.7.1 SALES & OPERATING INCOME

Scotts International. EU Vat number: PL 6772247784

12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 BAUSCH & LOMB INCORPORATED
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 AMNEAL PHARMACEUTICALS LLC.
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL ANALYSIS
12.7.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.7.4 KEY DEVELOPMENTS

12.4.2 FINANCIAL OVERVIEW

Scotts International. EU Vat number: PL 6772247784

12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 ALCON
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 AKORN OPERATING COMPANY LLC
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 VIATRIS INC.
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS



To place an Order with Scotts International:

Ophthalmic Topical Therapeutics Market Forecast till 2030

Market Report | 2023-11-15 | 148 pages | Market Research Future

Print this form					
☐ - Complete the re	levant blank fields and sign				
Send as a scann	ned email to support@scotts-interr	national.com			
ORDER FORM:					
Select license	License			Price	
		\$4950.00			
Enterprisewide Price					
			VAT		
			Total		
*Please circle the releva	ant license option. For any questions p	lease contact support@sco	otts-international.com or 0048 603 3	94 346.	
	t 23% for Polish based companies, ind				
	'				
Email*		Phone*			
First Name*		Last Name*			
Job title*					
Company Name*		EU Vat / Tax ID / NI	P number*		
Address*		City*			
Zip Code*		Country*			
		Date	2025-05-12		
		Signature			